UroGen Pharma Ltd. Ordinary Shares Earnings Dividend

UroGen Pharma Ltd. Ordinary Shares’s revenue jumped 151.6% since last year same period to $50.96Mn in the Q1 2026. On a quarterly growth basis, UroGen Pharma Ltd. Ordinary Shares has generated 34.68% jump in its revenue since last 3-months.

UroGen Pharma Ltd. Ordinary Shares’s net profit jumped 46.23% since last year same period to $-23.57Mn in the Q1 2026. On a quarterly growth basis, UroGen Pharma Ltd. Ordinary Shares has generated 10.58% jump in its net profits since last 3-months.

UroGen Pharma Ltd. Ordinary Shares’s net profit margin jumped 78.63% since last year same period to -46.26% in the Q1 2026. On a quarterly growth basis, UroGen Pharma Ltd. Ordinary Shares has generated 33.61% jump in its net profit margins since last 3-months.

UroGen Pharma Ltd. Ordinary Shares’s earning per share (EPS) estimates for the current quarter stand at -0.38 - a 20.83% jump from last quarter’s estimates.

UroGen Pharma Ltd. Ordinary Shares’s earning per share (EPS) estimates for the current year stand at -0.38.

UroGen Pharma Ltd. Ordinary Shares’s earning per share (EPS) jumped 48.91% since last year same period to -0.47 in the Q1 2026. This indicates that the UroGen Pharma Ltd. Ordinary Shares has generated 48.91% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. UroGen Pharma Ltd. Ordinary Shares’s return on assets (ROA) stands at -0.27.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. UroGen Pharma Ltd. Ordinary Shares’s return on equity (ROE) stands at -14.81.